Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3348600 | Diagnostic Microbiology and Infectious Disease | 2006 | 8 Pages |
Abstract
We evaluated the ability of 60 Italian clinical microbiology laboratories in detecting and reporting β-lactam resistance phenotypes in Enterobacteriaceae. Laboratories received 5 well-characterized isolates producing extended-spectrum β-lactamases (ESBLs), 2 hyperproducers of chromosomal enzymes, and 3 quality control strains. The performances in antimicrobial susceptibility testing (AST) were different depending on the species and type of ESBL produced. High rates of very major errors (up to 56%) were observed for ESBL producers when testing cephalosporins and aztreonam, especially in the case of CTX-M-1-producing Escherichia coli and TEM-52-producing Proteus mirabilis. Isolates hyperproducing chromosomal enzymes were erroneously reported as ESBL producers in approximately 20% of cases. Detection of ESBLs is still a problem for clinical microbiology laboratories. Overall, performances in AST appear to be better with Klebsiella spp. producing well-known enzymes (e.g., SHV type) than with strains producing emerging enzymes (e.g., CTX-M type) or organisms not well recognized as ESBL producers (e.g., P. mirabilis).
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Francesco Luzzaro, Giovanni Gesu, Andrea Endimiani, Giuseppe Ortisi, Sergio Malandrin, Laura Pagani, Gian Maria Rossolini,